The incretins: a link between nutrients and well-being

Rémy Burcelin*
UMR 5018 CNRS-UPS and IFR 31, Rangueil Hospital, L1 Bldg, BP 84225 Toulouse 31432 cedex 4, France

The glucoincretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), are intestinal peptides secreted in response to glucose or lipid intake. Data on isolated intestinal tissues, dietary treatments and knockout mice strongly suggest that GIP and GLP-1 secretion requires glucose and lipid metabolism by intestinal cells. However, incretin secretion can also be induced by non-digestible carbohydrates and involves the autonomic nervous system and endocrine factors such as GIP itself and cholecystokinin. The classical pharmacological approach and the recent use of knockout mice for the incretin receptors have shown that a remarkable feature of incretins is the ability to stimulate insulin secretion in the presence of hyperglycaemia only, hence avoiding any hypoglycaemic episode. This important role is the basis of ongoing clinical trials using GLP-1 analogues. Since most of the data concern GLP-1, we will focus on this incretin. In addition, GLP-1 is involved in glucose sensing by the autonomic nervous system of the hepato-portal vein controlling muscle glucose utilization and indirectly insulin secretion. GLP-1 has been shown to decrease glucagon secretion, food intake and gastric emptying, preventing excessive hyperglycaemia and overfeeding. Another remarkable feature of GLP-1 is its secretion by the brain. Recently, elegant data showed that cerebral GLP-1 is involved in cognition and memory. Experiments using knockout mice suggest that the lack of the GIP receptor prevents diet-induced obesity. Consequently, macronutrients controlling intestinal glucose and lipid metabolism would control incretin secretion and would consequently be beneficial for health. The control of incretin secretion represents a major goal for new therapeutic as well as nutrition strategies for treating and/or reducing the risk of hyperglycaemic syndromes, excessive body weight and thus improvement of well-being.

Diabetes: Insulin secretion: Incretins: Inulin-type fructans

At the beginning of the 20th century and already 20 years before the discovery of insulin by Banting & Best (1922), Bayliss & Starling (1902) and Moore et al. (1906) showed that gut extract could control carbohydrate metabolism via the pancreas in response to factors arising from the intestine which could be used for the treatment of diabetes. In the late 1960s it was further demonstrated that an oral glucose load induced a higher insulin secretion than intravenously administered glucose while blood glucose levels were similar between the two modes of delivery, suggesting that glucose clearance was different and involved different mechanisms (Fig. 1; Perley & Kpnis, 1967). These authors importantly showed the relevance of the underlying mechanism in diabetic subjects which led to the concept of incretins (Creutzfeldt, 1979), i.e. factors secreted by the intestine in response to an oral load of glucose or lipid that increase glucose-stimulated insulin secretion. This important discovery was followed by the identification and the characterization of intestinal peptides. First, in the 1970s, the gastric inhibitory peptide (GIP) was uncovered by Brown and Pedersen as being part of the incretin effect (Brown & Pedersen, 1970; Brown, 1971). Ten years later it was evident that another intestinal peptide, the glucagon-like peptide-1 (GLP-1), also participated in the incretin effect (Holst, 1977; Ebert & Creutzfeldt, 1982; Ebert et al. 1983; Holst et al. 1987).

GLP-1 has been named upon sequence analysis of the proglucagon gene, which showed that this intestinal peptide has a high degree of homology with pancreatic glucagon (Bell et al. 1983). Interestingly, the coding sequence of a second GLP, named GLP-2, was also present on the same gene (Fig. 2). The precursor peptide containing all three hormones was named the pre-proglucagon or ‘big glucagon’. The corresponding gene is expressed in the intestine (L cells), the pancreatic islets (α-cells) and in the brain (Drucker, 1990; Creutzfeldt, 1992; Thorens & Waeger, 1993; Holst, 1997; Blazquez et al. 1998; Nauck, 1998; Goldstone et al. 2000). The tissue-specific release of intestinal GLP and pancreatic glucagon is due to the combined action of pro-convertases named PC1/3, PC2, furin and carboxypeptidases (Orskov et al. 1987; Rouille et al. 1994, 1995; Fig. 2). A remarkable feature of GLP-1 is to be entirely conserved among all mammalian species where the corresponding gene has been cloned.

The GIP is also produced as a propeptide but the corresponding gene codes for only one functional peptide, GIP (Moody et al. 1984; Takeda et al. 1987; Creutzfeldt, 1992).

The biological effects of incretins have mainly been focusing on the increased responsiveness to glucose of pancreatic β-cells for the secretion of insulin. A large number of review papers based on more than 800 manuscripts report mechanisms underlying incretin-stimulated insulin secretion. It is beyond the scope of this review to detail all these papers. It will rather focus on evidences showing that the incretins, and precisely GLP-1, could control glucose metabolism throughout the regulation of the autonomic nervous system. The data would be interpreted with regard to the putative role that the non-digestible oligosaccharides including inulin-type fructans may have on incretin’s secretion and actions.

Regulation of glucoincretin secretion

The L cells secreting GLP-1 are largely distributed in the lower gut ileum, colon and even rectum (Holst, 1994; Orskov et al.

Abbreviations: DPPIV, dipeptidyl peptidase IV; GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; NIDDM, non-insulin dependent diabetes mellitus.
*Corresponding author: Dr Rémy Burcelin, fax +33 562 17 09 05, email burcelin@toulouse.inserm.fr
The biologically active GLP-1 is secreted as a 7–37 or 7–36 amide peptide while the K cells releasing GIP, as a 42 amino acid sequence, are present essentially in the duodenum (Buchan et al. 1978). However, both peptides are inactivated by an aminopeptidase, the dipeptidyl peptidase IV (DPPIV), which is produced in high amounts by intestinal epithelial cells (Deacon et al. 1995a). The enzyme removes the two first amino acids histidine–alanine leaving a totally inactive form of the circulating peptide (Fig. 2). Hence, the half-life of the biologically active GLP-1 is of the order of 30s. Consequently, a small fraction, less than 10%, of the active peptide reaches the arterial blood stream to target the organs and an incretin gradient exists between the mesenteric/hepato-portal veins and the hepatic artery. The postprandial increase of incretin secretion is 5- to 10-fold compared to the fasting levels. However, the amount of biologically active peptide in the systemic blood is much lower than the secreted amount (Orskov et al. 1994, 1996; Deacon et al. 1995b; Herrmann et al. 1995; Rocca & Brubaker, 1995; Schirra et al. 1996). This already suggests that, since they are mostly degraded as soon as they are produced, the incretins should have a local role, i.e. at the vicinity of the mesenteric veins or the portal vein. Moreover, modifying the half-life of incretins (e.g. via changes in nutrition) could have significant effects. For example, one could suggest that the known effect of inulin-type fructans on intestinal epithelial growth could originate from a change in the cell composition of the intestinal wall and hence of the relative proportion of the DPPIV expressing cells. Consequently, the secreted incretins would be more or less degraded. However, whether the rapid degradation of incretins is an important regulatory mechanism avoiding their excessive action remains to be determined. In addition, one could also speculate that small molecules issued from inulin-type fructans fermentation by the intestinal flora could release by an aminopeptidase, the dipeptidyl peptidase IV (DPPIV), which is produced in high amounts by intestinal epithelial cells (Deacon et al. 1995a). The enzyme removes the two first amino acids histidine–alanine leaving a totally inactive form of the circulating peptide (Fig. 2). Hence, the half-life of the biologically active GLP-1 is of the order of 30s. Consequently, a small fraction, less than 10%, of the active peptide reaches the arterial blood stream to target the organs and an incretin gradient exists between the mesenteric/hepato-portal veins and the hepatic artery. The postprandial increase of incretin secretion is 5- to 10-fold compared to the fasting levels. However, the amount of biologically active peptide in the systemic blood is much lower than the secreted amount (Orskov et al. 1994, 1996; Deacon et al. 1995b; Herrmann et al. 1995; Rocca & Brubaker, 1995; Schirra et al. 1996). This already suggests that, since they are mostly degraded as soon as they are produced, the incretins should have a local role, i.e. at the vicinity of the mesenteric veins or the portal vein. Moreover, modifying the half-life of incretins (e.g. via changes in nutrition) could have significant effects. For example, one could suggest that the known effect of inulin-type fructans on intestinal epithelial growth could originate from a change in the cell composition of the intestinal wall and hence of the relative proportion of the DPPIV expressing cells. Consequently, the secreted incretins would be more or less degraded. However, whether the rapid degradation of incretins is an important regulatory mechanism avoiding their excessive action remains to be determined. In addition, one could also speculate that small molecules issued from inulin-type fructans fermentation by the intestinal flora could release

Fig. 1. Oral glucose absorption induced higher plasma insulin levels than intravenous glucose injection. (A) Plasma insulin and (B) plasma glucose concentrations in mice injected with glucose orally or intravenously (personal data). The data show that while the glycaemic levels were similar in both groups of mice, the plasma insulin concentration was dramatically higher in the mice receiving glucose orally. This effect is attributed to the incretins glucagon-like peptide-1 and gastric inhibitory peptide being secreted by the intestine in response to oral glucose only.

Fig. 2. Proglucagon processing leads to the secretion of glucagon-like peptide-1 (GLP-1) and other related peptides in intestinal L cells. The pre-proglucagon peptide is composed of a signal peptide, a glicentin-related polypeptide (GRPP), glucagon, GLP-1, GLP-2, and intervening sequences (IP). The pre-proglucagon is first matured into proglucagon when a peptidase removes the signal peptide sequence. The proglucagon is then matured into GLP-1, GLP-2 and glicentin by the action of pro-convertases (ProC) and carboxypeptidases (CpE). The GLP-1 produced is then rapidly inactivated by the dipeptidyl peptidase IV (DPPIV) that removes the His–Ala residue in the N-terminal.
DPPIV inhibitors preventing the massive degradation of GLP-1 in the colon.

The incretin secretagogues are numerous, being nutrients, essentially carbohydrates and lipids (Knapper et al. 1995; Ritzel et al. 1997), hormones, cholecystokinin, GIP itself (Fukase et al. 1992; Roberge et al. 1996; Damholt et al. 1999), miscellaneous neural hormones and neuromediators (Ikeda et al. 1993; Balk et al. 1997). The most potent secretagogue seems to be a mix of fat and carbohydrate (Nordt et al. 1991; Knapper et al. 1995). While the metabolism of carbohydrate might be important for the secretion of GLP-1, it is not considered essential. Indeed, even though numerous carbohydrates including glucose, fructose and galactose induce GLP-1 secretion (Ritzel et al. 1997), whereas inhibitors of glucose metabolism such as 2-deoxyglucose and glucosamine inhibit GLP-1 secretion (Ritzel et al. 1997), still other data show that non-metabolized carbohydrate such as 3-O-methylglucose and methyl-α-D-glucoside stimulates GLP-1 secretion (Ritzel et al. 1997). This last piece of evidence suggests that other carbohydrate-derived structures like non-digestible inulin-type fructans could control GLP-1 secretion through a mechanism not involving their fermentation. Whether receptors at the luminal side of the intestinal cells could be activated by inulin-type fructans remains to be determined. The secretion of GLP-1 is, however, dependent upon the integrity of the autonomic nervous system and essentially upon the signal sent by the vagus nerve (Nauck et al. 1996; Wettergren et al. 1997). In addition to nutrients, it has been shown, in a fetal rat intestinal cell model, that the secretion of glucagon-like immunoreactive peptides was stimulated by cholecystokinin-8 (Fehmann et al. 1990, 1991), a gastrin-releasing peptide, calcitonin gene-related peptide and by GIP, with GIP being the most potent factor at least in rodents (Brubaker, 1991). Similarly, in isolated rat intestinal tissues, the cholineric agonist betanechol stimulated the secretion of GLP-1 while atropin inhibited the effect, revealing the role of the autonomic nervous system (Herrmann-Rinke et al. 1995). GLP-1 secretion was inhibited by somatostatin (Brubaker, 1991). In addition, the activation of neuropeptide factors and of the parasympathetic nervous system during intestinal glucose delivery has been shown to stimulate GLP-1 secretion (Plaisancie et al. 1995; Plant & Durrant, 1997; Rocca & Brubaker, 1999).

Effect of inulin-type fructans on secretion of glucagon-like peptide-1

Few reports are available with regard to the role of inulin-type fructans on the control of incretin secretion. It has been reported that rats given a diet supplemented with 30% inulin-type fructans for 2 weeks had significantly increased plasma GLP-1 and insulin levels following an oral glucose load (Reimer & McBurney, 1996; Kok et al. 1998a,b). Consequently, the glycaemic level of the rats was lower. In addition, GIP and GLP-1 concentrations were significantly higher in the serum of oligofructose-fed rats and the caecal GLP-1 pool was also higher. This latter data was related to an increased GLP-1 positive cell proliferation. Indeed, ileal proglucagon mRNA was increased, suggesting an additional trophic effect of inulin-type fructans on intestinal epithelial cells (Kok et al. 1998a). This effect was proportional to the amount of oligofructose in the diet. The improved glycaemic control could also be due to increased insulin sensitivity or through mechanisms independent of insulin action.

Incretins stimulate insulin secretion

Extended data show that incretins stimulate insulin secretion. After the cloning of the corresponding receptors, it was shown that the cellular mechanisms involve the intracellular increase of cAMP and Ca fluxes (Goke et al. 1989; Fridolf & Ahren, 1991, 1993; Gallwitz et al. 1993; Thoren & Waebier, 1993; Thorens et al. 1993; van Eyl et al. 1994; Widmann et al. 1994; Holz et al. 1995; Volz et al. 1995). The cAMP activates protein kinase A that mediates numerous actions triggering the exocytosis of insulin. The most remarkable effect of incretins is the ability to stimulate insulin secretion only in the presence of glucose stimulatory concentrations increasing β-cell glucose responsiveness. The number of reports detailing this observation is too large to be uniformly cited and only major observations are referred to (Kreymann et al. 1987; Mojsov et al. 1987; Orskov et al. 1988, 1996; Shima et al. 1988; Nathan et al. 1991; Goke et al. 1993; Holz et al. 1993; Nauck et al. 1993a; Zawalich et al. 1993; Hargrove et al. 1995; Jehle et al. 1995; Kolligs et al. 1995; Qualmann et al. 1995; Volz et al. 1995; Wang et al. 1995; Zawalich & Zawalich, 1996; Drucker, 1998; Ahren & Pacini, 1999; Tseng et al. 1999). Consequently, insulin secretion would stop when plasma glucose starts dropping below the physiological concentration of approximately 5 mM, preventing the occurrence of iatrogenic hypoglycaemia. This characteristic makes incretins major candidates for the treatment of hyperglycaemic syndromes (Nauck et al. 1993c; Byrne & Goke, 1996; Holst, 1996; Nauck, 1996; Willms et al. 1996; Ahren et al. 1997; Goke et al. 1997; Burcelin et al. 1999; Juhl et al. 2000).

Another strategy to improve the glycaemic control of diabetic patients and which has been largely used is based upon the inhibition of DPP IV (Ahren et al. 2000). One would suggest that due to the lack of specificity of the enzyme, the inhibitor might affect a large number of other neuropeptides. However, such secondary effects have not been reported and hence the strategy seems promising for the treatment of non-insulin dependent diabetes mellitus (NIDDM). No genetic association has been observed with mutations in the GLP-1 receptor (Tanizawa et al. 1994; Zhang et al. 1994), suggesting that compensatory mechanisms via the GIP secretion might exist. Hence, studies with double mutations on both incretin receptors should shed some light upon the important role of the intestinal hormones for the control of glucose metabolism. The secretion profiles of incretins during diabetes and obesity have been reported but there are still discordant data. First reports showed that in twins with NIDDM, GLP-1 secretion was decreased during oral glucose ingestion (Vaag et al. 1996). However, the intensity of the diseases and the presence of family members with diabetes were associated with the impaired GLP-1 secretion. In this study GIP secretion was normal. In obese patients, it has been reported that secretion of both GIP and GLP-1 was excessive following an oral glucose load. This impairment was more pronounced in obese diabetic patients, suggesting that chronic hyperglycaemia would maintain the aetiology of diabetes. The origin of these discrepancies is not yet understood but could be related to the multiplicity of the aetiology of diabetes.
Incretins regulate glucose homeostasis through non-β-cell mediated effects

In addition to the effects of incretins on insulin secretion, the improved glycaemic control of GLP-1-treated NIDDM patients is associated with a glucagonostatic effect of the intestinal hormone. Indeed, glucagon secretion is reduced in hyperglycaemic patients when infused with GLP-1 (Orskov et al. 1988; Komatsu et al. 1989; Creutzfeldt et al. 1996). Similarly to insulin, the lowering of plasma glucagon level is stopped when glycaemia drops below normal levels. However, it is unclear whether GLP-1 receptors are present at the surface of the α pancreatic cells (Campos et al. 1994), which would suggest that the regulatory effect of incretins would be on other cells connected to the α pancreatic cells such as brain cells (Shimizu et al. 1987; Kans et al. 1988; Utenthal et al. 1992; Campos et al. 1994; Goke et al. 1995; Wei & Mosjov, 1995; Alvarez et al. 1996). Indeed, the glucagon secretion is strongly dependent upon the autonomic nervous system (Rizza et al. 1979; Cryer, 1981; Gerich et al. 1990). Glucose sensors mostly located in the brain detect glycaemic variations and send a signal towards the pancreas to control glucagon secretion (Oomura et al. 1969, 1974; Oomura, 1981; Biggers et al. 1989; Frizzell et al. 1993). We recently showed that this message was dependent upon the expression of the extra-pancreatic glucose transporter GLUT2 (Burcelin & Thorens, 2001).

The GLP-1 receptor has been described several times in cerebral cells (Shimizu et al. 1987; Kans et al. 1988; Utenthal et al. 1992; Campos et al. 1994; Goke et al. 1995; Wei & Mosjov, 1995; Alvarez et al. 1996). Its functions have not been elucidated but could, at least in part, be associated with cognition and memory (During et al. 2003; Mattson et al. 2003). Indeed, when GLP-1 was administered into the cerebral ventricle of rats, the latency to a task was reduced as a matter of increased spatial learning. The co-infusion of exendin 9–39 completely blocked the effect of GLP-1. Interestingly, this effect was cholinergic-dependent since the injection of the cholinergic receptor agonist arecolin enhanced the effect of GLP-1. Similarly, the injection of the cholinergic receptor blocker the effect of GLP-1. Interestingly, this effect was cholinergic-dependent since the injection of the cholinergic receptor agonist arecolin enhanced the effect of GLP-1. Similarly, the injection of the cholinergic receptor blocker exendin 9–39 blocks the inhibitory effect of GLP-1 and potentiates the effect of orexigenic factors such as neuropeptide Y. To determine the cerebral structures involved, the authors have quantified c-fos as a marker of neuronal activation. Following GLP-1 injection, c-fos exclusively appeared in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala. The labels were masked by the injection of exendin 9–39. In addition, leptin injection increased GLP-1 production in the brain stem (Goldstone et al. 2000); it was therefore suggested that part of the anorectic effect of leptin could be mediated via the release of GLP-1. Hence, inulin-type fructans activating the release of GLP-1 into the brain by stimulating the vagus nerve signal would enhance memory and cognition.

Incretins control the autonomic nervous system

During a meal, the intestine absorbs energetic nutrients, such as glucose and lipids. While lipids reach the lymphatic stream and are delivered to the systemic circulation, carbohydrates are delivered directly to the hepato-portal vein. A positive gradient of carbohydrate concentration between the hepato-portal vein and the arterial blood is thus established (Fig. 3). Glucose-sensitive units present in the hepato-portal vein detect this gradient (Niijima, 1969; Pagliassotti et al. 1991, 1996) and send a signal through the hepatic branch of the vagus nerve to target tissues such as the liver (Niijima, 1985; Gardemann et al. 1986; Moore & Cherrington, 1996; Moore et al. 1996; Stumpel & Jungermann, 1997), the hypothalamus (Schmitt, 1973; Shimizu et al. 1983), insulin-secreting β-cells (Berthoud et al. 1983), the brain stem (Adachi et al. 1984) and the adrenal glands (Hevener et al. 1997, 2000). The specific cellular functions that are activated then participate to the adaptation of the body to the new metabolic situation. We previously described that one of the consequences of activating the hepato-portal glucose sensor was to increase blood glucose clearance (Fig. 4) and utilization in a subset of tissues, mostly heart, soleus and brown adipose tissue (Burcelin et al. 2000). The activation of whole body glucose clearance induced a paradoxical hypoglycaemic effect (Fig. 4). We also showed that activation of this sensor was inhibited by somatostatin and that it required the presence of the glucose transporter GLUT2 (Burcelin et al. 2000a). Along the same line of investigation we infused GLP-1 and glucose into the portal vein of normal mice (Burcelin et al. 2001). The infusion of GLP-1 did not modify portal glucose sensitivity. In the presence or absence of portal GLP-1 infusion, plasma insulin levels and glucose clearance were similarly increased by glucose, suggesting that portal GLP-1 has no role on the nervous reflex stimulating insulin secretion and glucose clearance. However, when the same experiment was performed in GLP-1 receptor knockout mice, hyperglycaemia developed during the portal glucose infusion suggesting that the receptor was important (Fig. 5). We further identified the location where the
GLP-1 receptor was important by infusing the inverse agonist exendin 9–39 via different routes. No effects were detected when the exendin 9–39 was infused into the systemic circulation (i.e. through the femoral vein). However, when the peptide was infused along with glucose into the portal vein, hyperglycaemia rather than hypoglycaemia developed suggesting that, in the portal vein, the GLP-1 receptor provided the sensitivity to glucose (Fig. 5). During the portal glucose infusion, plasma insulin did also increase. Few reports suggest that sensory nerves could contribute to insulin secretion via an indirect route involving the enteric autonomic

![Fig. 4. Portal glucose infusion increased glucose clearance and induced a paradoxical hypoglycaemic state. Glucose or saline (S) was infused at a low rate into the hepato-portal vein (P) to activate the corresponding sensor or into the femoral vein (F) as a negative control. (A) Glucose clearance was increased in mice infused with glucose into the portal vein, while only a small effect was observed in the femoral infused mice. (B) The portal glucose infusion but not the femoral glucose infusion induced hypoglycaemia. (C) Plasma insulin levels were increased by the portal glucose infusion despite hypoglycaemia, suggesting a reflex activated by the portal glucose sensor and independent of the peripheral glycaemic level. Plasma insulin concentration rose in the blood of femoral infused mice as a consequence of hyperglycaemia. Adapted from Burcelin et al. (2000b).]
The glucagon-like protein-1 (GLP-1) receptor is required for hepatoportal vein glucose sensing. GLP-1 receptor knockout mice were infused with glucose into the portal vein (Po in GLP-1 Rc KO). In these animals hyperglycaemia rather than hypoglycaemia developed, suggesting a role of the GLP-1 receptor in the maintenance of glucose responsiveness. In control mice glucose was infused in the presence of exendin 9–39 (the inverse agonist of the GLP-1 receptor) into the portal vein (Po + Ex in Cont) or into the femoral vein (Po + fEx in Cont). Hyperglycaemia developed with exendin 9–39 when infused with glucose into the portal vein but not into the femoral vein, denoting that the GLP-1 receptor in the portal vein was important to maintain the glucose responsiveness of the sensor.

Fig. 5. The glucagon-like protein-1 (GLP-1) receptor is required for hepatoportal vein glucose sensing. GLP-1 receptor knockout mice were infused with glucose into the portal vein (Po in GLP-1 Rc KO). In these animals hyperglycaemia rather than hypoglycaemia developed, suggesting a role of the GLP-1 receptor in the maintenance of glucose responsiveness. In control mice glucose was infused in the presence of exendin 9–39 (the inverse agonist of the GLP-1 receptor) into the portal vein (Po + Ex in Cont) or into the femoral vein (Po + fEx in Cont). Hyperglycaemia developed with exendin 9–39 when infused with glucose into the portal vein but not into the femoral vein, denoting that the GLP-1 receptor in the portal vein was important to maintain the glucose responsiveness of the sensor.

Fig. 6. The glucagon-like protein-1 (GLP-1) receptor is necessary for the early stimulation of insulin secretion during oral glucose absorption. Mice underwent an oral glucose injection and plasma insulin levels were assessed 2 and 30 min later. The figure shows that the GLP-1 receptor and gastric inhibitory peptide (GIP) receptor knockout mice are glucose-intolerant and that the double mutant is even more glucose-intolerant. Insulin secretion was not induced after 2 min in the absence of the GLP-1 receptor only, showing the GLP-1-dependent regulatory reflex. The GIP receptor was not involved in this process. In addition, plasma insulin concentration was reduced after 30 min in all mutant mice showing the role of the incretin receptor at the level of the β-cell. The inset of (A) shows the area under the curve (AUC) of the glucose tolerance test.
injection of GLP-1 which could delay gastric emptying while no effect was observed when the vagal nerve was cut earlier (Imeryuz et al. 1997).

**Lessons from genetically engineered mice**

The incretin receptors have been knocked out in the mouse. The first study on the GLP-1 receptor knockout reported that the mice developed normally, but exhibited increased levels of blood glucose following oral glucose challenge (Scrocchi et al. 1996). This was associated with a reduced circulating insulin level. The intracerebroventricular administration of GLP-1 did not produce its satiating effect in the mutant mice, but no difference in body weight or feeding behaviour was noticed. Similarly, mice with a targeted mutation of the GIP receptor have higher blood glucose and impaired initial insulin response after oral glucose load although glycemia was normal after a meal (Miyawaki et al. 1999). When fed a high-fat diet, the knockout mice were still normoglycaemic but with dramatically increased insulin secretion as a compensatory mechanism. The GIP receptor is more widely expressed in the body than the GLP-1 receptor. Noteworthy, it is expressed in adipose tissue, which is now considered as an important regulator of glucose homeostasis. In addition to the action of incretin on insulin secretion, the present study shows that the use of mutant mice for the corresponding receptors has uncovered the major role of GLP-1 in the activation of extra-pancreatic glucose sensors for the control of glucose metabolism. However, due to the multicellular distribution of the incretin receptors, tissue-specific deletion would nail down the role of each receptor for the control of nutritional homeostasis.

**Conclusion**

The secretion of incretins in response to nutrients leads to:

(1) the control of pancreatic insulin and glucagon secretions;
(2) the maintenance of extra-pancreatic glucose sensitivity;
(3) the regulation of gastric emptying and food intake;
(4) the maintenance of cognitive functions and memory.

Consequently, all these effects are major regulators of glucose and lipid homeostasis affecting secondarily body weight. Whether nutrients like insulin-type fructans can positively interfere with the incretin system remains to be assessed using appropriate analyses in adapted animal models of nutritional diseases and genetically engineered mice to bring out the molecular bases of the action of insulin-type fructans on digestive functions.

**References**


Nature 301, 397–403.


GLP-1 and well-being

S155


